New cocktail of four drugs shows promise for tough prostate cancer
NCT ID NCT02913196
First seen May 08, 2026 · Last updated May 09, 2026 · Updated 1 time
Summary
This early-phase study tested a combination of four drugs (apalutamide, abiraterone, docetaxel, and prednisone) in 16 men with metastatic castrate-resistant prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose of apalutamide when given with the other three drugs. Researchers also tracked changes in PSA levels and tumor growth. The study was completed, but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.